6. Arena Pharmaceuticals (ARNA), which is currently seeking approval of its weight loss drug lorcaserin, has seen its share price fall 10% in 2010 thus far. The Food and Drug Administration has tentatively scheduled an advisory committee meeting to review the company's new drug application for lorcaserin on Sept. 16.
Consensus: Of the analysts covering Arena, eight, or 40%, advocate buying the stock. The other 12 analysts rating the stock suggest that investors hold it.
Closing Price: $3.23 (June 2)Bullish Case: Davenport analysts have a buy rating for speculative investors in Arena, noting that lorcaserin's new drug application has reasonable chances of gaining approval from the FDA given the "extensive base of 7,000 plus patients that participated in the Phase III trials," which showed "very good tolerability." The firm has a price target of $5 to $6 a share. Bearish Scenario: JMP Securities, which has a market perform rating on Arena, says that while the firm remains confident that lorcaserin "demonstrated an approvable efficacy profile in Phase III based on the current FDA guidance and a favorable safety profile, any indication that the FDA is looking for greater weight loss would be viewed as negative for lorcaserin."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV